At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Aflibercept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
In Brief
A Phase 2 clinical trial evaluating Aflibercept and foselutoclax for Diabetic Macular Edema and 8 related conditions. Completed, enrolled 52 participants across 19 sites.
Detailed Summary
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: * Assess the efficacy of foselutoclax compared to aflibercept * Assess the safety and tolerability of foselutoclax
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartAug 2023
First PostedAug 2023
Primary CompletionJan 2025
Study CompletionApr 2025
TodayJul 2026
First PostedAug 25, 2023
Enrollment StartAug 23, 2023
Primary CompletionJan 21, 2025
Study CompletionApr 8, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 2.9 years ago
Interventions
Afliberceptdrug
Anti-VEGF control
foselutoclaxdrug
Experimental drug